Corticosteroid exposure and cumulative effects in patients with eczema

• DOI: 10.1016/j.anai.2022.09.031
• Publication Date: 2022-09-30T17:58:40Z
• Authors: Kelly Barta; Luz S. Fonacier; Mary Hart; Peter Lio; Kathryn Tullos; Belinda Sheary; Tonya A. Winders
• Keywords: Discontinuation

Individuals with eczema may have substantial lifetime corticosteroid exposure, increasing the risk of corticosteroid-related side effects.To conduct a patient survey evaluating exposure and its cumulative effects in individuals eczema.The multinational online was conducted between November 5, 2020, January 11, 2021. Participants were aged 18 years or older (n = 1889) caregiver child 271) diagnosed having by medical professional.All participants reported using corticosteroids. Average duration topical (TCS) use 15.3 adults 3.6 children; 75% used TCS 1 to 2 times day 50% applied 15 30 days/mo. Frequency could not be determined varying prescription potencies. Oral 36% (23% for eczema), average 8.4 courses 8.1 children. Corticosteroids non-eczema atopic conditions 49% participants. In TCS, 83% 64% children experienced worsening symptoms over time. Development new increased greater number treatments longer but been owing progression. Symptoms consistent steroid withdrawal syndrome after discontinuation many participants.Reported throughout their experience placed at negative outcomes. are critical component treatment patients. However, careful prescribing practices monitoring needed avoid effects. When possible, corticosteroid-sparing strategies should explored.